Related Experiment Videos
Pharmacokinetics of atenolol in patients with renal impairment
Insights
Atenolol
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Atenolol is a cardioselective beta-adrenoceptor blocking agent used for hypertension.
- Renal impairment significantly affects drug pharmacokinetics.
- Understanding atenolol's elimination is crucial for dose adjustment.
Purpose of the Study:
- To investigate atenolol pharmacokinetics in hypertensive patients with varying renal function.
- To assess the impact of renal impairment on atenolol half-life and clearance.
- To evaluate the efficacy and safety of chronic atenolol treatment.
Main Methods:
- Pharmacokinetic analysis of atenolol in 33 hypertensive patients.
- Acute and chronic dosing regimens were employed.
- Glomerular filtration rate (GFR) was correlated with atenolol blood clearance.
Main Results:
- Atenolol half-life increased with renal insufficiency.
- Atenolol blood clearance significantly correlated with GFR, highlighting kidney's role in elimination.
- Chronic treatment reduced blood pressure, heart rate, and plasma renin activity.
- No correlation between atenolol blood levels and pharmacodynamic effects was found.
- Antihypertensive effect correlated with pretreatment plasma renin activity.
Conclusions:
- Renal function is critical for atenolol elimination.
- Dose adjustments may be necessary in patients with impaired renal function.
- Atenolol effectively manages hypertension, with its efficacy linked to baseline renin levels.
Abstract:
The pharmacokinetics of atenolol, a new cardioselective beta-adrenoceptor blocking agent, were determined following both acute and chronic dosing in 33 hypertensive patients with widely differing levels of renal impairment. In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses. This value increased markedly in patients with renal insufficiency and the blood clearance of atenolol was found to have a significant correlation with the glomerular filtration rate. This demonstrated the importance of the kidneys in the elimination of the drug. After 8 weeks oral treatment with atenolol (100 mg twice daily) a significant decrease in blood pressure, heart rate and plasma renin activity was observed, but no correlation was established between the blood levels of atenolol and any of its pharmacodynamic effects. A positive correlation was found however between the anti-hypertensive action of atenolol and the pretreatment value of the plasma renin activity.